-
Je něco špatně v tomto záznamu ?
Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009
J. Srba, V. Descikova, J. Vlcek,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost)
od 2008-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- databáze faktografické MeSH
- farmakovigilance MeSH
- sběr dat MeSH
- systémy pro sběr zpráv o nežádoucích účincích léků organizace a řízení statistika a číselné údaje trendy MeSH
- zapojení pacienta metody MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
PURPOSE: Spontaneous reporting systems in European countries are crucial for collecting adverse drug reaction (ADR) reports. The aim of this study was to evaluate reporting activity among countries and their strategy to increase the number of reports. We also established the best measure for assessment quantity of reports. METHODS: This was a retrospective observational study based on questionnaires and annual reports. The most reliable measure of reporting was determined by Spearman correlation coefficients. RESULTS: Data collected in spontaneous reporting systems in 26 European countries were analysed. In 2007, 2008 and 2009, the average value of reports per year per million inhabitants based on the safety databases of countries was 208, 236, 286, respectively; in comparison, that of Eudra- Vigilance was 311, 453 and 435, respectively. Twelve countries reached a significant level for signal detection of ADRs in 2009. The population-based reporting ratio (PBRR) was correlated to the total expenditure on health (ρ=0.499, p=0.023, n=21), public expenditure on health (ρ=0.477, p=0.035, n=20), density of physicians (ρ=0.336, p=0.136, n=21) and expenditure on pharmaceuticals (ρ=0.365, p=0.114, n=20). Strategies of regulatory authorities to increase reporting were determined. CONCLUSIONS: The results of this study make several noteworthy contributions regarding national spontaneous reporting systems. The relevance of the PBRR for the measurement reporting activity is clearly supported by the current findings. This study also shows that there is a general trend towards increased reporting activity. This is maintained by regional centres and encouragement of reporting. A further study would be helpful to assess the effectiveness of reporting systems at both the national and European level.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000963
- 003
- CZ-PrNML
- 005
- 20240104144039.0
- 007
- ta
- 008
- 130108s2012 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00228-012-1219-4 $2 doi
- 035 __
- $a (PubMed)22294060
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Srba, Jindrich $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic. jindrich.srba@gmail.com
- 245 10
- $a Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009 / $c J. Srba, V. Descikova, J. Vlcek,
- 520 9_
- $a PURPOSE: Spontaneous reporting systems in European countries are crucial for collecting adverse drug reaction (ADR) reports. The aim of this study was to evaluate reporting activity among countries and their strategy to increase the number of reports. We also established the best measure for assessment quantity of reports. METHODS: This was a retrospective observational study based on questionnaires and annual reports. The most reliable measure of reporting was determined by Spearman correlation coefficients. RESULTS: Data collected in spontaneous reporting systems in 26 European countries were analysed. In 2007, 2008 and 2009, the average value of reports per year per million inhabitants based on the safety databases of countries was 208, 236, 286, respectively; in comparison, that of Eudra- Vigilance was 311, 453 and 435, respectively. Twelve countries reached a significant level for signal detection of ADRs in 2009. The population-based reporting ratio (PBRR) was correlated to the total expenditure on health (ρ=0.499, p=0.023, n=21), public expenditure on health (ρ=0.477, p=0.035, n=20), density of physicians (ρ=0.336, p=0.136, n=21) and expenditure on pharmaceuticals (ρ=0.365, p=0.114, n=20). Strategies of regulatory authorities to increase reporting were determined. CONCLUSIONS: The results of this study make several noteworthy contributions regarding national spontaneous reporting systems. The relevance of the PBRR for the measurement reporting activity is clearly supported by the current findings. This study also shows that there is a general trend towards increased reporting activity. This is maintained by regional centres and encouragement of reporting. A further study would be helpful to assess the effectiveness of reporting systems at both the national and European level.
- 650 _2
- $a systémy pro sběr zpráv o nežádoucích účincích léků $x organizace a řízení $x statistika a číselné údaje $x trendy $7 D016907
- 650 _2
- $a sběr dat $7 D003625
- 650 _2
- $a databáze faktografické $7 D016208
- 650 _2
- $a zapojení pacienta $x metody $7 D010358
- 650 _2
- $a farmakovigilance $7 D060735
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Deščíková, Veronika $7 xx0312300
- 700 1_
- $a Vlcek, Jiri
- 773 0_
- $w MED00001613 $t European journal of clinical pharmacology $x 1432-1041 $g Roč. 68, č. 7 (2012), s. 1057-63
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22294060 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20240104144033 $b ABA008
- 999 __
- $a ok $b bmc $g 963745 $s 799127
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 68 $c 7 $d 1057-63 $i 1432-1041 $m European journal of clinical pharmacology $n Eur J Clin Pharmacol $x MED00001613
- LZP __
- $a Pubmed-20130108